Understanding Familial Thrombomodulin Anomalies
At a Glance
Familial thrombomodulin anomalies are rare conditions caused by THBD variants. Depending on the variant, a person may be more prone to bleeding, dangerous clotting, or atypical hemolytic uremic syndrome (aHUS). A genetic result alone does not confirm a diagnosis.
Finding out you have a mutation in the THBD gene—which leads to a familial thrombomodulin anomaly—can be an overwhelming and confusing experience. One of the most difficult parts of this diagnosis is that the condition is what doctors call a “paradox.” Depending on the specific way your gene is affected, some specific variants may make you bleed too easily, while others act as a susceptibility factor for dangerous microscopic clotting [1][2]. Please note that a THBD genetic result alone does not establish a bleeding or aHUS diagnosis.
If you feel like your doctors are learning about this alongside you, you are likely correct. Because these anomalies are exceptionally rare and often identified only within specific families, most local physicians will never have seen a case in their entire careers [1][2]. This page will help you understand what this gene does and why it behaves so differently from person to person.
The Role of Thrombomodulin
To understand this condition, you first need to know what thrombomodulin does. Think of your blood vessels as a highway and your blood as the traffic. Thrombomodulin is a protein that sits on the lining of your blood vessels (endothelium) and acts like a highly sophisticated traffic controller [3].
Its main job is to catch a protein called thrombin. Normally, thrombin is the “master builder” of blood clots. However, when thrombomodulin catches thrombin, it changes thrombin’s behavior entirely. Instead of building a clot, the two work together to activate a natural “off-switch” for clotting called Protein C [4]. In a healthy body, this ensures that blood flows smoothly and clots only form when and where they are actually needed.
Why the Condition is Paradoxical
The reason this condition is so confusing is that different mutations in the THBD gene break the “traffic controller” in different ways.
- The Bleeding Branch: In some families, the mutation causes the “traffic controller” to break off the blood vessel wall and float freely in the blood in high amounts [1]. This “floating” thrombomodulin is hyper-efficient; it turns off the clotting process so effectively that the blood cannot form a stable clot when it needs to. This leads to symptoms like easy bruising or heavy bleeding after a minor injury [1][5].
- The Clotting Branch: In other cases, the mutation prevents the “traffic controller” from working at all. Thrombin is never “caught,” so the “off-switch” for clotting is never flipped [2]. This leaves the body in a state where it is much more likely to form dangerous clots or develop a severe condition called aHUS (atypical hemolytic uremic syndrome), where tiny clots damage small blood vessels and organs like the kidneys [6][7]. This is distinct from an ordinary blood clot in the leg (DVT).
Navigating an Exceptionally Rare Diagnosis
It is important to validate the frustration you may feel regarding the lack of clear answers. Familial thrombomodulin anomalies are so rare that there are no reliable estimates for how many people have them worldwide [8]. Most of what medical science knows about this condition comes from studying a handful of individual families [1].
Because it is so rare:
- Standard tests may not be enough: Your local laboratory might show “normal” results for common clotting tests even if you are experiencing severe symptoms [1].
- Genetics are complex: Penetrance and triggers vary substantially by variant and whether it is proven pathogenic; not everyone who carries a THBD mutation will get sick. Doctors call this incomplete penetrance, meaning other factors—like an infection or surgery—might be needed to “trigger” the condition [9][7].
- Specialization is key: Because this condition affects both the blood and the blood vessel walls, management often requires a team that understands both hematology (blood) and the complement system (a part of the immune system that can cause clotting when it malfunctions) [6][10].
While the rarity of this condition means there isn’t a “one-size-fits-all” guidebook, understanding whether your mutation causes a “loss of function” (clotting) or a “gain of function” (bleeding) is the first step in working with your doctors to create a personal care plan.
Common questions in this guide
How can a THBD mutation cause either bleeding or clotting?
Does a THBD genetic result prove that I have a bleeding disorder or aHUS?
Can routine blood-clotting tests be normal with a THBD anomaly?
What can trigger symptoms in someone with a THBD variant?
Which specialists should I see for a familial thrombomodulin anomaly?
What does it mean if my THBD variant is called a VUS?
Get notified when new evidence is published on Familial thrombomodulin anomalies.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (10)
- 1
A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.
Westbury SK, Whyte CS, Stephens J, et al.
Journal of thrombosis and haemostasis : JTH 2020; (18(9)):2209-2214 doi:10.1111/jth.14990.
PMID: 32634856 - 2
Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis.
Van Laer C, Lavend'homme R, Baert S, et al.
Blood 2025; (145(17)):1929-1942 doi:10.1182/blood.2024026454.
PMID: 39841007 - 3
Thrombomodulin: a multifunctional receptor modulating the endothelial quiescence.
Giri H, Biswas I, Rezaie AR
Journal of thrombosis and haemostasis : JTH 2024; (22(4)):905-914 doi:10.1016/j.jtha.2024.01.006.
PMID: 38266676 - 4
Thrombomodulin: A key regulator of intravascular blood coagulation, fibrinolysis, and inflammation, and a treatment for disseminated intravascular coagulation.
Suzuki K
Proceedings of the Japan Academy. Series B, Physical and biological sciences 2025; (101(2)):75-97 doi:10.2183/pjab.101.006.
PMID: 39694492 - 5
A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.
Okada M, Tominaga N, Honda G, et al.
Blood advances 2020; (4(12)):2631-2639 doi:10.1182/bloodadvances.2019001155.
PMID: 32556284 - 6
Nephrotic-Range Proteinuria and Peripheral Edema in a Child: Not Only Idiopathic Nephrotic Syndrome.
Dolcemascolo V, Vivarelli M, Colucci M, et al.
Case reports in nephrology and dialysis 2016; (6(3)):120-127 doi:10.1159/000449423.
PMID: 27904864 - 7
TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells.
Sartain SE, Turner NA, Moake JL
Journal of immunology (Baltimore, Md. : 1950) 2016; (196(2)):832-45 doi:10.4049/jimmunol.1500960.
PMID: 26673143 - 8
Thrombomodulin (THBD) gene variants and thrombotic risk in a population-based cohort study.
Manderstedt E, Halldén C, Lind-Halldén C, et al.
Journal of thrombosis and haemostasis : JTH 2022; (20(4)):929-935 doi:10.1111/jth.15630.
PMID: 34970867 - 9
Genotypic analysis of a large cohort of patients with suspected atypical hemolytic uremic syndrome.
Connaughton DM, Bhai P, Isenring P, et al.
Journal of molecular medicine (Berlin, Germany) 2023; (101(8)):1029-1040 doi:10.1007/s00109-023-02341-4.
PMID: 37466676 - 10
Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex.
Heurich M, Preston RJ, O'Donnell VB, et al.
Thrombosis research 2016; (145()):84-92.
PMID: 27513882
This page explains familial thrombomodulin anomalies and THBD genetic findings for informational purposes only; it does not replace medical advice. Ask a hematology or genetics specialist to interpret your specific results and symptoms.